Skip to content
COVID19, Science

Key biological pathway reveals insights into long COVID brain fog

UNSW Sydney 4 mins read

The identification of a metabolic pathway could lead to answers and new treatments for those experiencing brain fog because of long COVID. 

Researchers from UNSW Sydney and St. Vincent’s Hospital have identified a key pathway, involved in inflammation, which appears to be activated in people with long COVID who have symptoms of ‘brain fog’.  

Scientists from the School of Psychology and Faculty of Medicine & Health found that of the study cohort of 128 people, those who had a prolonged activation of the kynurenine pathway were more likely to have mild cognitive deficits 12 months after developing COVID-19. They also found that these symptoms were less likely to improve over time.  

Patients who took part in this study had mild to moderate acute COVID-19 and were enrolled in the St Vincent's COVID-19 ADAPT study, a longitudinal study led by Professor Gail Matthews

“Together, this study and a previous study in the ADAPT program show that long COVID brain fog is associated with a dysregulation of the immune response,” says Associate Professor Lucette Cysique, lead author of the study. “The current study specifically found that an important metabolic pathway – the kynurenine pathway – is linked to the cognitive changes we’re seeing in this group of patients.” 

The study, published in Annals of Clinical and Translational Neurology, helps demonstrate that there is a biological change underlying brain fog in people who have long COVID as a result of mild acute COVID-19 infection.  

“I think when patients go to the doctor's with brain fog, it may be dismissed as a psychological problem. Our study speaks to the contrary, that there is a real biological mechanism behind long COVID brain fog,” A/Prof. Cysique says. 

The discovery opens up possibilities for identifying and treating people who are experiencing the cognitive effects of long COVID and perhaps long COVID in general. “These findings lay the foundation for the kynurenine pathway as a potential diagnostic and monitoring marker, as well as a possible therapeutic target,” A/Prof. Cysique says. 

Long COVID and 'brain fog'

Current evidence compiled by the World Health Organisation (WHO) suggests approximately 10–20 per cent of people experience a variety of mid and long-term effects after they recover from their initial illness. In fact, up to 100 different symptoms have been recorded as part of the long COVID disease profile.  

“Long COVID is a multi-organ disease, so people are differently affected across several of their body functions. This is not surprising as the immune system is involved across all body functions,” says A/Prof. Cysique. “However, we now know that besides fatigue, cognitive changes are the most common symptoms associated with long COVID.”

The cognitive dysfunctions experienced by those with long COVID manifest most often as a lack of mental focus or clarity, or mental fatigue that is unusual compared to one’s previous capacity, especially after a cognitively demanding task (for example reading complex instructions, participating in a meeting that demands high concentration level, watching a documentary on a topic that is new and complex). This is associated with short-term memory problems, difficulty in multi-tasking or concentration over long periods of time. 

As A/Prof. Cysique explains, the best descriptor of brain fog would be a flu-like physical and mental fatigue lasting months, although with some fluctuations.  

“With a little introspection, we can all imagine how long-term flu-like physical and mental fatigue would impact everyday function,” says A/Prof. Cysique. “And, we are talking of mostly working-age people. Hence, these types of deficits can affect work efficiency to some degree and probably contribute to the economic impact of the pandemic.”

Long-term follow up of COVID patients

While this study included only unvaccinated patients, because the testing was conducted before patients received their first vaccine, the majority of people in the study had long COVID as a result of mild COVID-19 infection. “With vaccination, many of us will still experience mostly mild symptoms. Hence the results are still relevant, especially in the context of reinfection,” says A/Prof. Cysique.  

As part of A/Prof. Cysique’s research, the cohort was followed up at two, four, and 12 months. “At each of these points, the patients went through lots of tests, including on their mental health, physical health and cognitive health, and patients also had tests for various blood biomarkers on four occasions.” 

The team decided to investigate the activation of the kynurenine pathway based on previous experience of studying the pathway in other infectious diseases. In addition, the immune precursor of the kynurenine pathway was shown to be associated with persistent chest and fatigue symptoms in a previous paper also part of the ADAPT study, published last year in Nature Immunology.   

“While this latest study is a cohort study with factors that remain unmeasured, the convergence of evidence for the importance of the kynurenine pathway in long COVID, and the associated brain fog, is not by chance,” says A/Prof. Cysique. 

Discovery of an underlying mechanism

A/Prof. Cysique and her team discovered that at two months, when the kynurenine pathway was the most activated, 60 per cent of those who showed mild cognitive deficits, such as in attention/concentration and speed processing, showed an abnormal activation of the kynurenine pathway – abnormal meaning above the known abnormal level in reference samples of the same age. 

“As the immune response takes place, it activates the kynurenine pathway across a period of four months in average – this is much longer than it should be. Because the kynurenine pathway is pro-inflammatory, the entire body, including the brain, is flooded by inflammatory products over a prolonged period. And we know that the kynurenine pathway impacts the central nervous system,” says A/Prof. Cysique.  

Significantly, no other blood biomarkers, sex, or clinical factors – such as pre-existing or COVID-associated mental health, disease severity or respiratory function, and olfaction – were associated with cognition.  

Opening doors to further research

In April 2023, the government announced new research funding for long COVID as a result of the long COVID parliamentary enquiry. It shows that the government recognises long COVID as a serious issue that demands urgent solutions. 

This study has opened the door for further research into potential biomarkers and future therapies for those living with long COVID. “The long COVID clinics are still full of patients and the hospitals are still struggling with the issue,” says A/Prof. Cysique. “We hope that our study can provide some hope to people who are suffering from long COVID.”  

The team are keen to continue building on their research by extending the study cohort to vaccinated patients and to continue the investigation up to 24 months after the infection date.  

“We are also in contact with a Dutch research group who also find that a prolonged activation of the KP is involved in COVID-19 brain changes and want to start a trial,” says A/Prof. Cysique.

Contact details:
Lilly Matson
UNSW Science
0426 656 007


More from this category

  • Science
  • 15/06/2024
  • 00:22
Argonne National Laboratory

Argonne and a Moroccan University Sign Agreement to Advance Green Energy Tech and Computing

LEMONT, Ill.–BUSINESS WIRE– The U.S. Department of Energy’s (DOE) Argonne National Laboratory and University Mohammed VI Polytechnic (UM6P) have signed a memorandum of understanding…

  • Contains:
  • Science
  • 14/06/2024
  • 20:22
Kirin Holdings Company, Limited

Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary

Contributing to the health of consumers around the world through both health food and skincare businesses Aim to become one of the largest health…

  • Contains:
  • Science
  • 11/06/2024
  • 22:07
Greene Tweed

Greene Tweed Extends Global Reach With Completion of Manufacturing Facility in Korea

The new expansion will increase the manufacturing leader's capacity and capabilities for the semiconductor market.LANSDALE, PA / ACCESSWIRE / June 11, 2024 / Greene Tweed, a leading global manufacturer of high-performance thermoplastics, composites, seals, and engineered components, has announced the completion of its new manufacturing facility in Ochang, Cheongju-si, Chungcheongbuk-do, Republic of Korea. The milestone marks a significant expansion of Greene Tweed's global footprint and reinforces its commitment to delivering innovative solutions and exceptional service to their customers worldwide with its flagship Chemraz® product line. With construction now complete, the new facility is poised to commence sample production immediately and…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.